HCA HCA Healthcare
Guidance cut creates margin of safety; HCA's scale franchise is mispriced at 18% discount.
The story
HCA is the largest for-profit hospital operator, leveraging regional density and scale efficiencies to sustain mid-teens operating margins in a structurally growing healthcare market. The 2026 guidance cut and securities fraud probe introduce near-term uncertainty around payer mix and governance, but the core franchise—high-acuity volumes, disciplined capex, and payer negotiating power—remains intact. At ~$405 vs. an intrinsic near $495, the market is pricing in margin compression and litigation risk that look overdone relative to HCA's demonstrated resilience through multiple cycles.
Trimming Y1 revenue growth from 6.5% to 5.5% reflects the 2026 guidance cut and payer-mix headwinds; margin target, sales-to-capital, beta, and horizon are unchanged as the core economics and reinvestment efficiency haven't structurally changed. Failure probability nudged from 2% to 3% for incremental litigation/governance risk, still low given HCA's scale and balance-sheet capacity to absorb adverse outcomes.
Value drivers
| Revenue growth (Y1) | 5.5% |
| Terminal growth | 2.5% |
| Forecast horizon | 8y |
| Target operating margin | 15.5% |
| Years to target margin | 7 |
| Sales-to-capital | 1.85 |
| Beta | 1.05 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 8.3% |
| Terminal WACC | 8.2% |
Valuation bridge
| PV of explicit FCFF | 54.30B |
| PV of terminal value | 102.44B |
| Equity value | 104.80B |
| ÷ shares → per share | $484.04 |
News
bearish -0.40 · 8 articles
- The Bull Case For HCA Healthcare (HCA) Could Change Following 2026 Guidance Cut And Payer Mix Strain
- HCA Healthcare (HCA) Faces Securities Fraud Investigation With Shareholder Risks In Focus
- HCA Healthcare (HCA) Could Be 11% Below Fair Value As Guidance Gets Cut
- Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
- Is HCA Healthcare Stock Underperforming the Nasdaq?
- HCA Healthcare (HCA) Navigates Patient Volume Challenges While Reporting Growth
- 2 Profitable Stocks Worth Investigating and 1 We Turn Down
- Can Operational Resiliency Protect HCA's Long-Term Profitability?
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 82.30B | 5.5% | 15.6% | 10.17B | 2.32B | 7.85B | 7.24B |
| 2 | 86.48B | 5.1% | 15.6% | 10.67B | 2.26B | 8.41B | 7.17B |
| 3 | 90.49B | 4.6% | 15.6% | 11.15B | 2.17B | 8.98B | 7.06B |
| 4 | 94.31B | 4.2% | 15.6% | 11.61B | 2.06B | 9.55B | 6.93B |
| 5 | 97.88B | 3.8% | 15.5% | 12.03B | 1.93B | 10.10B | 6.77B |
| 6 | 101.16B | 3.4% | 15.5% | 12.42B | 1.78B | 10.65B | 6.59B |
| 7 | 104.12B | 2.9% | 15.5% | 12.77B | 1.60B | 11.17B | 6.38B |
| 8 | 106.73B | 2.5% | 15.5% | 13.09B | 1.41B | 11.69B | 6.16B |
Key risks
- Payer mix deterioration as managed-care pressure intensifies on commercial rates
- Securities fraud investigation could yield material settlements or governance overhang
- Labor cost inflation outpacing pricing power, compressing margins below 15%
Catalysts
- 2026 guidance stabilization or upward revision as volumes recover
- Resolution of securities fraud investigation with manageable financial impact
- Continued share repurchases at discount to intrinsic value